BCDA   $1.17  5.41% Market Closed After Close 1.15 -1.71%

BioCardia, Inc.
Last Events:

2023-08-06 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-06 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-06 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-05 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-04 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-08-03 Trend pattern changed from восходящий клин to расширяющаяся формация.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.


Current temperature: 4.75
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 0.64
High with % probability:
Analyst Recommendations:
Number of estimates 2
Target Price Mean 15.50
Mean unverified/preliminary 15.50 / 15.50
Target Price Low / High 6.00 / 25.00
Median / STD DEV 15.50 / 13.44
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi Sell None None
macd None None None
stoch None None None
ma20 Buy Buy ActivelyBuy
ma50 None None None
ma100 Buy ActivelyBuy None
Candlestick PatternSept. 17, 2026 Bearish Engulfing - is characterized by a large black body engulfing a preceding smaller white body, which appears during a downtrend. Considered to be a bearish reversal pattern.
ISIN US09060U6064
ceo Dr. Peter A. Altman Ph.D.
Website https://www.biocardia.com
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.